Director — Kwaku Temeng: A director resigned citing a disagreement with the Board regarding strategic direction and governance practices, indicating a non-routine departure with potential signal of internal conflict.

Regulation FD Disclosure. On July 29, 2026, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on August 10, 2026 and payable August 31, 2026. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…

Results of Operations and Financial Condition. On July 29, 2026, Core Laboratories Inc. issued a press release announcing its financial results for the second quarter of 2026.

Results of Operations and Financial Condition. On April 29, 2026, Core Laboratories Inc. issued a press release announcing its financial results for the first quarter of 2026.

Regulation FD Disclosure. On April 29, 2026, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 11, 2026 and payable June 1, 2026. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…

Results of Operations and Financial Condition. The Original Form 8-K included, as Exhibit 99.1 thereto, a copy of the Company’s press release that was issued on February 4, 2026 announcing the financial results of the Company for the quarter and year ended December 31, 2025 (the “Earnings Release”). Subsequent to the Company’s fourth quarter earnings call on February 5, 2026 and during the preparation of its audited consolidated financial statements to be included in the Company’s Annual Repo…

Results of Operations and Financial Condition. On February 4, 2026, Core Laboratories Inc. issued a press release announcing its financial results for the fourth quarter of 2025 and year ending December 31, 2025.

Regulation FD Disclosure. On February 4, 2026, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on February 16, 2026 and payable March 9, 2026. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E…

Regulation FD Disclosure. On October 22, 2025, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on November 3, 2025 and payable November 24, 2025. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…

Results of Operations and Financial Condition. On October 22, 2025, Core Laboratories Inc. issued a press release announcing its financial results for the third quarter of 2025.

Results of Operations and Financial Condition. On July 23, 2025, Core Laboratories Inc. issued a press release announcing its financial results for the second quarter of 2025.

Entry into a Material Definitive Agreement. On July 22, 2025, Core Laboratories Inc. (the "Parent Borrower") and Core Laboratories (U.S.) Interests Holdings, Inc. (the "U.S. Borrower" and together with the Parent Borrower, collectively the "Company") entered into a Ninth Amended and Restated Credit Agreement (henceforth referred to as the "Amended Credit Agreement") with various financial institutions who are parties to the Amended Credit Agreement (collectively, the "Lenders"), with Bank of…

Regulation FD Disclosure. On July 23, 2025, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on August 4, 2025 and payable August 25, 2025. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in

Results of Operations and Financial Condition. On April 23, 2025, Core Laboratories Inc. issued a press release announcing its financial results for the first quarter of 2025.

Regulation FD Disclosure. On April 23, 2025, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 5, 2025 and payable May 27, 2025. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…

Regulation FD Disclosure. On January 29, 2025, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on February 10, 2025 and payable March 3, 2025. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E…

Results of Operations and Financial Condition. On January 29, 2025, Core Laboratories Inc. issued a press release announcing its financial results for the fourth quarter of 2024 and year ending December 31, 2024.

Results of Operations and Financial Condition. On October 23, 2024, Core Laboratories Inc. issued a press release announcing its financial results for the third quarter of 2024.

Regulation FD Disclosure. On October 23, 2024, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on November 4, 2024 and payable November 25, 2024. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…

Regulation FD Disclosure. On July 24, 2024, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on August 5, 2024 and payable August 26, 2024. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…

Results of Operations and Financial Condition. On July 24, 2024, Core Laboratories Inc. issued a press release announcing its financial results for the second quarter of 2024.

Regulation FD Disclosure. On April 24, 2024, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 6, 2024 and payable May 28, 2024. The full text of the press release is set forth in Exhibit 99.1 attached hereto. The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…

Results of Operations and Financial Condition. On April 24, 2024, Core Laboratories Inc. issued a press release announcing its financial results for the first quarter of 2024.

Chief Accounting Officer — Kevin Daniels: The departure of the Chief Accounting Officer was an orderly succession with an immediate internal promotion of a long-tenured employee, indicating no disruption or dispute.